deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 2-arm NCT03774654

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

Allogeneic Natural Killer T-Cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies

Sponsor: Baylor College of Medicine

Interventions CD19.CAR-aNKT cells
Updated 19 times since 2019 Last updated: Jun 27, 2025 Started: Jun 22, 2020 Primary completion: Jun 20, 2026 Completion: Feb 28, 2035
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Refractory B-Cell Non-Hodgkin Lymphoma and Refractory B-Cell Small Lymphocytic Lymphoma and is currently ongoing. Baylor College of Medicine leads this study, which shows 19 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2019 – ~Dec 2019 · 11 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jun 2025 · 8 months · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – present · 11 months · monthly snapshot

Change History

19 versions recorded
  1. Aug 2025 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Jul 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Jun 2025 — Jul 2025 [monthly]

    Active Not Recruiting PHASE1

    Status: RecruitingActive Not Recruiting

  4. Oct 2024 — Jun 2025 [monthly]

    Recruiting PHASE1

  5. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1

Show 14 earlier versions
  1. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  2. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1

  3. Jun 2023 — Jul 2024 [monthly]

    Recruiting PHASE1

  4. Mar 2023 — Jun 2023 [monthly]

    Recruiting PHASE1

  5. Sep 2022 — Mar 2023 [monthly]

    Recruiting PHASE1

  6. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE1

  7. Feb 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  8. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1

  9. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  10. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE1

    Status: Not Yet RecruitingRecruiting

  11. May 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE1

  12. Feb 2020 — May 2020 [monthly]

    Not Yet Recruiting PHASE1

  13. Dec 2019 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE1

  14. Jan 2019 — Dec 2019 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Baylor College of Medicine
  • Center for Cell and Gene Therapy, Baylor College of Medicine
  • National Cancer Institute (NCI)
  • The Methodist Hospital Research Institute
Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations